These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 10407251)

  • 21. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.
    Mellors JW; Muñoz A; Giorgi JV; Margolick JB; Tassoni CJ; Gupta P; Kingsley LA; Todd JA; Saah AJ; Detels R; Phair JP; Rinaldo CR
    Ann Intern Med; 1997 Jun; 126(12):946-54. PubMed ID: 9182471
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The values of quantitative serum HIV-1 RNA levels and CD4 cell counts for predicting survival time among HIV-positive individuals with CD4 counts of < or = 50 x 10(6) cells/l.
    Coakley EP; Samore MH; Gillis JM; Hughes MD; Hammer SM
    AIDS; 2000 Jun; 14(9):1147-53. PubMed ID: 10894278
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of HIV-1 RNA, CD4 cell count, and CD4 Cell count slope for progression to AIDS and death in untreated HIV-1 infection.
    Mellors JW; Margolick JB; Phair JP; Rinaldo CR; Detels R; Jacobson LP; Muñoz A
    JAMA; 2007 Jun; 297(21):2349-50. PubMed ID: 17551128
    [No Abstract]   [Full Text] [Related]  

  • 24. Impact of missing data due to selective dropouts in cohort studies and clinical trials.
    Touloumi G; Pocock SJ; Babiker AG; Darbyshire JH
    Epidemiology; 2002 May; 13(3):347-55. PubMed ID: 11964938
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men.
    Sterling TR; Vlahov D; Astemborski J; Hoover DR; Margolick JB; Quinn TC
    N Engl J Med; 2001 Mar; 344(10):720-5. PubMed ID: 11236775
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiretroviral effects on HIV-1 RNA, CD4 cell count and progression to AIDS or death: a meta-regression analysis.
    Mills EJ; Kelly S; Bradley M; Mollon P; Cooper C; Nachega J
    HIV Med; 2008 Nov; 9(10):849-57. PubMed ID: 18795965
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A controlled trial of granulocyte macrophage-colony stimulating factor during interruption of HAART.
    Fagard C; Le Braz M; Günthard H; Hirsch HH; Egger M; Vernazza P; Bernasconi E; Telenti A; Ebnöther C; Oxenius A; Perneger T; Perrin L; Hirschel B;
    AIDS; 2003 Jul; 17(10):1487-92. PubMed ID: 12824786
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Empirical power for distribution-free tests of incomplete longitudinal data with applications to AIDS clinical trials.
    Kuhn AM; DeMasi RA
    J Biopharm Stat; 1999 Aug; 9(3):401-16. PubMed ID: 10473028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Considerations in choosing a primary endpoint that measures durability of virological suppression in an antiretroviral trial.
    Gilbert PB; Ribaudo HJ; Greenberg L; Yu G; Bosch RJ; Tierney C; Kuritzkes DR
    AIDS; 2000 Sep; 14(13):1961-72. PubMed ID: 10997401
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of plasma HIV RNA among highly active antiretroviral therapy users.
    Tarwater PM; Gallant JE; Mellors JW; Gore ME; Phair JP; Detels R; Margolick JB; Muñoz A
    AIDS; 2004 Dec; 18(18):2419-23. PubMed ID: 15622318
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Joint effects of HIV-1 RNA levels and CD4 lymphocyte cells on the risk of specific opportunistic infections.
    Williams PL; Currier JS; Swindells S
    AIDS; 1999 Jun; 13(9):1035-44. PubMed ID: 10397533
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Two-sample tests of area-under-the-curve in the presence of missing data.
    Spritzler J; DeGruttola VG; Pei L
    Int J Biostat; 2008 Jan; 4(1):Article 1. PubMed ID: 20231907
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drop-outs and a random regression model.
    Overall JE
    J Biopharm Stat; 1997 Jul; 7(3):383-402. PubMed ID: 9252832
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Longitudinal patterns of HIV type 1 RNA among individuals with late disease progression.
    Gange SJ; Mellors JW; Lau B; Detels R; Phair JP; Muñoz A; Margolick JB
    AIDS Res Hum Retroviruses; 2001 Sep; 17(13):1223-9. PubMed ID: 11559421
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analyzing laboratory marker changes in AIDS clinical trials.
    Dawson JD; Lagakos SW
    J Acquir Immune Defic Syndr (1988); 1991; 4(7):667-76. PubMed ID: 2051307
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment history and baseline viral load, but not viral tropism or CCR-5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatment.
    Bratt G; Karlsson A; Leandersson AC; Albert J; Wahren B; Sandström E
    AIDS; 1998 Nov; 12(16):2193-202. PubMed ID: 9833861
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS.
    AIDS; 1998 Oct; 12(14):F151-60. PubMed ID: 9792371
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Missing covariates in longitudinal data with informative dropouts: bias analysis and inference.
    Roy J; Lin X
    Biometrics; 2005 Sep; 61(3):837-46. PubMed ID: 16135036
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIV-infected infants and children.
    Palumbo PE; Raskino C; Fiscus S; Pahwa S; Fowler MG; Spector SA; Englund JA; Baker CJ
    JAMA; 1998 Mar; 279(10):756-61. PubMed ID: 9508151
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV-1 viral load and CD4 cell count in untreated children with vertically acquired asymptomatic or mild disease. Paediatric European Network for Treatment of AIDS (PENTA).
    AIDS; 1998 Mar; 12(4):F1-8. PubMed ID: 9520161
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.